Wednesday, June 10, 2026
🇺🇸 FDA

biotech · PTSD - Post Traumatic Stress Disorder · P1b: Advanced Solid Tumors · CMPX

Compass Therapeutics

Compass Therapeutics clinical programs — 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
80 Guest Street, Suite 601, Boston, MA 02135, US HQ
2014 Founded
54 Employees
Public company Type
CMPX · NYSE Ticker
Company details
Status
Public
HQ
80 Guest Street, Suite 601, Boston, MA 02135, US
Founded
2014
Employees
54
Programs
15
Drugs
3
Patents
100
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Compass Therapeutics projects

15 ClinicalTrials.gov programs sponsored by Compass Therapeutics.

Compass Therapeutics has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

15 programs

Clinical programs

  1. COMP360 psilocybin

    Compass Therapeutics

    PTSD - Post Traumatic Stress Disorder

    phase 3 small molecule active

    1 trial

  2. CTX-009

    Compass Therapeutics

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  3. Psilocybin

    Compass Therapeutics

    Treatment Resistant Depression

    phase 3 small molecule active

    7 trials

  4. Psilocybin

    Compass Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    2 trials

  5. CTX-009

    Compass Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  6. CTX-009

    Compass Therapeutics

    Glioblastoma

    phase 2 small molecule active

    1 trial

  7. CTX-009 (ABL001)

    Compass Therapeutics

    P1b: Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  8. Gemcitabine

    Compass Therapeutics

    Metastatic Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  9. Psilocybin

    Compass Therapeutics

    Treatment-Resistant Major Depressive Disorder

    phase 2 small molecule terminated

    1 trial

  10. Psilocybin

    Compass Therapeutics

    Post Traumatic Stress Disorder

    phase 2 small molecule completed

    1 trial

  11. Psilocybin

    Compass Therapeutics

    Anorexia Nervosa

    phase 2 small molecule completed

    2 trials

  12. Psilocybin

    Compass Therapeutics

    Body Dysmorphic Disorders

    phase 2 small molecule completed

    1 trial

  13. CTX-10726

    Compass Therapeutics

    Gastroesophageal Cancer (GC)

    phase 1 small molecule active

    1 trial

  14. CTX-471

    Compass Therapeutics

    Locally Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  15. CTX-8371

    Compass Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Compass Therapeutics have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.